GDUFA III Agreement Will Constrain Fee Revenue Increases
Executive Summary
Generic user fee program's next iteration will also offer improved mid- and post-assessment communications for sponsors to receive feedback from US FDA.
You may also be interested in...
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.
New GDUFA Workload Formula Will Not Include Inspections Until FY 2025 Fee-Setting
Capacity planning adjustment that will help calculate generic drug user fees will not include inspections at first to allow more time for time reporting system implementation.
Califf: Industry Should Be Reminded Of US FDA’s Separate Development Advice, Application Assessment Roles
Experts wonder why the FDA Commissioner commented on a system seemingly working fine, but Califf says it is necessary to remember the potential conflict between the two roles.